Moderna Balance Sheet Health

Financial Health criteria checks 6/6

Moderna has a total shareholder equity of $12.8B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $16.7B and $3.9B respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$8.52b
EquityUS$12.82b
Total liabilitiesUS$3.91b
Total assetsUS$16.73b

Recent financial health updates

No updates

Recent updates

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29
Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03
Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 18
Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Financial Position Analysis

Short Term Liabilities: MRNA's short term assets ($9.6B) exceed its short term liabilities ($2.4B).

Long Term Liabilities: MRNA's short term assets ($9.6B) exceed its long term liabilities ($1.5B).


Debt to Equity History and Analysis

Debt Level: MRNA is debt free.

Reducing Debt: MRNA had no debt 5 years ago.

Debt Coverage: MRNA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MRNA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.